Anaphylatic reactions ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydramine led to lower anaphylatic reactions ‐ not reported compared with placebo; GRADE not reported.
1 finding from 1 review
Death ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydramine led to lower death ‐ not reported compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydramine led to lower adverse events compared with placebo; GRADE not reported.
1 finding from 1 review
Allergic reactions (urticaria with or without pruritus) ‐ Intention‐to treat analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
It is very uncertain whether acetaminophen plus Diphenhydramine changes allergic reactions (urticaria with or without pruritus) ‐… compared with placebo (very low certainty).
1 finding from 1 review
Mean change in BCVA at 1 month (logMAR) · people with acute non‐arteritic CRAO
1 finding from 1 review
Quality of life measures at 1 month · people with acute non‐arteritic CRAO
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at 1 month · people with acute non‐arteritic CRAO
1 finding from 1 review
Abstinence · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants abstinent at end of treatment compared with placebo (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants experiencing adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in participants withdrawn due to adverse effects compared with placebo (low certainty).
1 finding from 1 review
Completion of scheduled treatment · cannabis dependence
Δ9‐Tetrahydrocannabinol preparation showed no clear difference in completion of scheduled treatment compared with placebo (low certainty).
1 finding from 1 review
Adverse events · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower adverse events compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Fever · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine showed no clear difference in fever ‐ Per protocol analysis compared with placebo (Unit of randomisation: transfusion) (low certainty).
1 finding from 1 review
Anaphylatic reactions ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower anaphylatic reactions ‐ not reported compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Hives ‐ Per protocol analysis · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine showed no clear difference in hives ‐ Per protocol analysis compared with placebo (Unit of randomisation: transfusion) (low certainty).
1 finding from 1 review
Death ‐ not reported · patients with requirement of prophylaxis to avoid allergic and febrile non‐haemolytic transfusion reactions
Acetaminophen plus Diphenhydrammine led to lower death ‐ not reported compared with placebo (Unit of randomisation: transfusion); GRADE not reported.
1 finding from 1 review
Salivary S. mutans level · Humans with salivary bacteria measured
Salivary F. nucleatum and Actinobacillus levels were not associated with a clear difference.
1 finding from 1 review
OR 2.39 [1.00, 5.71]
1 study
GRADE not reported
Mean GI symptom scores (IBDQ‐B) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acute and late GI toxicity (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
Summary of findings: Aminosalicylates probably leads to higher acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).
1 finding from 1 review
Diarrhoea (grade 2+) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found